Jeffrey Wiese
Suggested For You
perspectives
September 3rd, 2026
From Signal to System: FDA Approval Does Not Mean Treatment Can Begin the Next Morning
perspectives
August 27th, 2026
Risk-Based Data Management: Moving Beyond Traditional Data Cleaning
perspectives
August 17th, 2026
From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer
webinar
September 10th, 2026
The Evolution of REMS: FDA Risk Management Considerations for Novel Risks Associated with Psychoactive Drugs
perspectives
August 11th, 2026
The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way
perspectives
August 7th, 2026
UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know
case study
July 31st, 2026
Delivering Strategic Biostatistics Support to Enable Phase 2b Funding Decisions
perspectives
July 31st, 2026
FDA Orphan Drug Designation Requirements: Key Mistakes to Avoid
perspectives
July 29th, 2026
From Signal to System: The Next Challenges for Psychedelic Therapies
webinar
August 20th, 2026
Risk-Based Data Management: Success Factors, Risks, and What Comes Next
perspectives
July 24th, 2026
FDA’s Latest Psychedelic Guidance: Key Changes and Implications for Sponsors
whitepaper
July 23rd, 2026
Lessons from Outside Pharma for Faster, More Usable Data